Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10411212 | 0.78 | — | — | |
| SCHEMBL558555 | 0.75 | PSMB8 (0.44) | TSHRRAB9ADYRK1AALDH1A1MAPT | |
| SCHEMBL1696135 | 0.75 | PSMD14 (0.36) | — | |
| SCHEMBL211528 | 0.75 | ALDH1A1 (0.44) | TSHRACHEL3MBTL1ALDH1A1MAPT | |
| SCHEMBL558291 | 0.75 | SMN1; SMN2 (0.44) | TSHRKDM4ERAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL6098342 | 0.75 | KDM4E (0.39) | PDPK1TSHRKDM4ERAB9AL3MBTL1 | |
| SCHEMBL2444608 | 0.75 | ALDH1A1 (0.44) | TSHRMMP2KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL4337978 | 0.72 | LIMK1 (0.39) | METAP2ALDH1A1HPGDHSD17B10RET | |
| SCHEMBL558130 | 0.72 | PSMB8 (0.35) | TSHRKDM4ERAB9AALDH1A1HPGD | |
| SCHEMBL8932315 | 0.72 | TTR (0.36) | TSHRCOMTALDH1A1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | claimed |
| EP-3294728-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | claimed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | claimed |
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | claimed |
| EP-2493894-B1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-29 | — | — | EP | claimed |
| EP-2428577-B1 | Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters | EASTMAN CHEM CO (US) | 2014-01-22 | — | — | EP | claimed |
| EP-2493893-B1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | claimed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | claimed |
| US-8278320-B2 | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | claimed |
| EP-2493893-A1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | claimed |
| US-20080306144-A1 | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors | EASTMAN CHEMICAL COMPANY | 2008-12-11 | — | — | US | claimed |
| WO-2008143777-A1 | HYDROQUINONE DERIVATIVE SKIN BRIGHTENING COMPOUNDS | EASTMAN CHEMICAL COMPANY (US) | 2008-11-27 | — | — | WO | claimed |
| US-20080286219-A1 | Hydroquinone derivative skin brightening compounds | EASTMAN CHEMICAL COMPANY | 2008-11-20 | — | — | US | claimed |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| EP-1732919-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2006-12-20 | — | — | EP | claimed |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | CHIRON CORPORATION (US) | 2005-11-17 | — | — | US | claimed |
| WO-2005095386-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2005-10-13 | — | — | WO | claimed |
| EP-0188001-B1 | OPTICAL INFORMATION RECORDING MEDIUM | KURARAY CO., LTD. (JP) | 1990-05-02 | — | — | EP | claimed |
| US-4686143-A | MONOAZOMETAL COMPLEX COMPOUND RECORDING LAYER | KURARAY CO., LTD. (JP) | 1987-08-11 | — | — | US | claimed |
| EP-0188001-A2 | Optical information recording medium | KURARAY CO., LTD. (JP) | 1986-07-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306144-A1 | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors | TYR, TH, HAAO | PDPK1 423/4885TSHR 4133/4885METAP2 1611/4885 |
| US-20080286219-A1 | Hydroquinone derivative skin brightening compounds | NQO1, CUTA, TYR | PDPK1 1861/4885TSHR 4349/4885METAP2 4137/4885 |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | MALT1, AKT1, PIK3CA | PDPK1 22/4885TSHR 2075/4885METAP2 3636/4885 |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | CYP3A5, ABCG2, ABCB1 | PDPK1 4290/4885TSHR 2791/4885METAP2 3237/4885 |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | PDPK1 666/4885TSHR 4313/4885METAP2 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.